Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Organisation › Details

MorphoSys (Group)

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". *

 

Period Start 1992-01-01 established
  Today MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Predecessor Max Planck Society for the Advancement of Science
Product Industry biopharmaceutical
Persons Person Moroney, Simon E. (MorphoSys 1992– CEO + Founder)
  Person 2 Holstein, Jens (MorphoSys 201105– CFO before Regional CFO Fresenius Kabi + Managing Director Fresenius Kabi Deutschland)
     
Region Region Martinsried
  Country Germany
  Street 7 Semmelweisstr.
  City 82152 Planegg
  Tel +49-89-89927-0
    Address record changed: 2018-07-24
     
Basic data Employees D: 101 to 500 (2017-12-31)
  Currency EUR
  Annual sales 66,790,840 (revenues, consolidated (2017) 2017-12-31)
  Profit -69,826,469 (2017-12-31)
  Cash 76,589,129 (2017-12-31)
     
    * Document for �About Section�: MorphoSys AG. (2/7/11). "Press Release: MorphoSys Strengthens Patent Position on Lead Program MOR103".
     
   
Record changed: 2018-04-12

Advertisement

Picture BioM Forum Translationl Medicine 2018 Würzburg Germany 600x100px

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top